Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source

Inclusion Criteria:

• • Subject signed inform consent

• Age > 18 years

• Not pregnant or breast feeding

• Patient capable of undergoing anesthesia

• Patient selected to undergo Whipple procedure or distal pancreatectomy

• Patient does not have metastatic disease

• Patients will have close margins

• No prior radiation therapy to the region for separate cancer

• Confirmed diagnosis of borderline resectable or locally advanced pancreaticadenocarcinoma

• Patient Received neoadjuvant chemoradiation (4-10 weeks prior to surgery)

• Chemotherapy was administered for 2-6 cycles with any combination of thefollowing agents:

• Gemcitabine + nb-paclitaxel

• FOLFIRINOX

• Neoadjuvant Chemoradiation was administered as IMRT or 3DCRT (up to 56 Gy), orSBRT (up to 36 Gy) with Pre-operative External beam dose (NCCN)

• up to 56 Gy (1.8-2.0 Gy per fractions) with concurrent gemcitabine,capecitabine, or infusional 5-fluorouracil

Exclusion Criteria:

• Not surgical candidate

• Any other invasive cancer in the past 5 years, except basal cell or squamous cellskin cancer

• An IRE candidate (IRE is Percutaneous irreversible electroporation)

• Recurrent or previously resected tumors

• Documented History of Alcoholism and or drug abuse

• Participant in other clinical trials